Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | GRN | P28799 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008355 | 0.93 | CDK8 (0.63) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL5011989 | 0.90 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL27617940 | 0.89 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL28757659 | 0.87 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL5012012 | 0.85 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5008529 | 0.85 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL14600240 | 0.84 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL5008769 | 0.83 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL27637099 | 0.82 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL5005312 | 0.81 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100448869-C | Anilinopyrazole derivatives for the treatment of diabetes | BAYER PHARMACEUTICALS CORP (US) | 2009-01-07 | — | — | CN | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| CN-1717401-A | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORP (US) | 2006-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.